Schizophrenia is a severe mental disorder characterized by psychosis and major disturbances in perception, thinking, and behavior, often causing substantial functional impairment across life domains. It is associated with persistent delusions, hallucinations, and disorganized thought or behavior.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.
Teva said the FDA accepted its New Drug Application for long-acting olanzapine for schizophrenia, with a decision expected later this year. The company also reported Austedo sales of $2.26 billion in 2025 and plans six biosimilar launches in 2026 and 2027.
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
The FDA approved milsaperidone for bipolar I disorder and schizophrenia, while COMP360 psilocybin met its primary endpoint in a second phase 3 trial for treatment-resistant depression. Phase 2a data showed intravenous DMT (SPL026) significantly reduced depressive symptoms in major depressive disorder patients.
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Researchers identify speech latency as a biomarker to enrich schizophrenia clinical trials, while a separate study finds clozapine more effective than alternatives for patients who fail initial antipsychotic treatment.
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604129 |
Transcranial Sonography and Machine Learning for Schizophrenia Identification |
NOT_YET_RECRUITING | |
| NCT07592884 |
A Randomized Controlled Trial of the Rochester Forensic Assertive Community Treatment Model in Minnesota |
COMPLETED | NA |
| NCT07586150 |
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) |
NOT_YET_RECRUITING | NA |
| NCT07585383 |
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects |
NOT_YET_RECRUITING | PHASE1 |
| NCT07571148 |
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users |
ACTIVE_NOT_RECRUITING | |
| NCT07557381 |
The Effect of Game-Based Intervention on the Cognition of Schizophrenia Patients |
RECRUITING | NA |
| NCT07557368 |
Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia |
RECRUITING | NA |
| NCT07549581 |
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode |
COMPLETED | PHASE1 |
| NCT07547384 |
Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. |
NOT_YET_RECRUITING | NA |
| NCT07534475 |
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT |
NOT_YET_RECRUITING | NA |
